Articles tagged with: Pomalidomide

News»

[ by | Feb 10, 2014 3:38 pm | 4 Comments ]
Pomalyst-Based Combination Regimens Presented At ASH 2013

At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster pre­sen­ta­tions about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.

Many of the presentations were about studies of Pomalyst (poma­lido­mide, Imnovid) and dex­a­meth­a­sone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (car­filz­o­mib), cla­rith­ro­my­cin (Biaxin), cyclo­phos­pha­mide (Cytoxan), or Doxil (doxorubicin lipo­somal), for relapsed and refractory myeloma. …

Read the full story »

News»

[ by | Jan 6, 2014 5:22 pm | 5 Comments ]
Additional Analyses Of Pomalyst Plus Low-Dose Dexamethasone Studies Presented At ASH 2013

More than twenty presentations about studies involving Pomalyst were pre­sented at this year’s meeting of the American Society of Hematology (ASH), which took place last month.

Several of these presentations were about the Phase 3 clinical trial that found Pomalyst (pomalidomide, Imnovid) plus low-dose dex­a­meth­a­sone (Decadron) significantly improved overall survival of relapsed and re­frac­to­ry myeloma pa­tients compared to high-dose dex­a­meth­a­sone alone (see related Beacon news).  This is the study that led to the ap­prov­al of pomalidomide in Europe, where it is marketed under the brand name …

Read the full story »

News»

[ by | Dec 13, 2013 9:16 pm | 3 Comments ]
ASH 2013 Multiple Myeloma Update - Day Three: Morning Oral Sessions

This Monday was the third day of the 2013 American Society of Hema­tol­o­gy (ASH) annual meeting, which was held in New Orleans.

More than any other day of the conference, Monday was packed with im­por­tant myeloma presentations, from 7:00 in the morning until almost 8:00 in the eve­ning.

This ASH update will summarize the oral presentation sessions about treat­ment-related myeloma studies that were held Monday morning. An ASH update that was published on Wednesday focused on the sessions that were held Monday afternoon and evening.

Monday morning started with …

Read the full story »

News»

[ by and | Dec 11, 2013 6:20 pm | Comments Off ]
ASH 2013 Multiple Myeloma Update - Day Three: Afternoon Oral Sessions

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.

This ASH update highlights most of …

Read the full story »

News»

[ by | Dec 9, 2013 1:13 pm | 2 Comments ]
ASH 2013 Multiple Myeloma Update - Day Two

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.

The myeloma study included in this …

Read the full story »